Physician profile
Duc Tran
NPI 1831130111
$6,304.35
in general payments reported to CMS, 2019-2025
30 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $218 · 2021: $862 · 2022: $962 · 2023: $1,667 · 2024: $1,236 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,673.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,057.83 | 2019-2025 | Durysta, Lumigan, Alphagan P |
| Alcon Vision LLC | $818.36 | 2021-2025 | Argos, Rocklatan, Clareon |
| Allergan, INC. | $610.77 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $452.28 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Glaukos Corporation | $434.63 | 2019-2024 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Idose |
| Mallinckrodt Hospital Products INC. | $398.93 | 2021-2025 | Acthar |
| Amgen INC. | $242.61 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $200.01 | 2019-2021 | |
| Horizon Therapeutics Plc | $143.08 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $131.09 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $102.51 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $90.02 | 2019-2022 | |
| Ocular Therapeutix, INC. | $75.51 | 2022 | |
| Ivantis, INC | $71.27 | 2019 | |
| Sight Sciences, INC. | $58.43 | 2022-2025 | Omni Surgical System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $56.84 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $39.04 | 2023 | Eylea Hd |
| Shire North American Group INC | $38.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $37.79 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $35.85 | 2025 | Xdemvy |
| Thea Pharma INC. | $32.74 | 2022-2025 | Iyuzeh |
| Dompe US, INC. | $32.50 | 2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $20.10 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $19.87 | 2021 | |
| Biotissue Holdings INC. | $19.50 | 2022 | |
| Astellas Pharma US INC | $17.89 | 2024 | Izervay |
| Merz North America, INC. | $17.50 | 2019 | |
| Beaver-Visitec International, INC. | $17.26 | 2023 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Rxsight INC | $14.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.